IFRX IFRX

InflaRx NV Stock Price

2.53
-0.07 (-2.69%)
Upgrade to Real-Time
Regular Market
2.53
Volume 63,211
Bid Price 2.52
Ask Price 2.54
News -
Day High 2.62

Low
0.7762

52 Week Range

High
5.6856

Day Low 2.50
Company Name Stock Ticker Symbol Market Type
InflaRx NV IFRX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.07 -2.69% 2.53 13:23:07
Open Price Low Price High Price Close Price Prev Close
2.59 2.50 2.62 2.60
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
424 63,211 $ 2.56 $ 161,525 - 0.7762 - 5.6856
Last Trade Time Type Quantity Stock Price Currency
13:23:06 4 $ 2.53 USD

Period:

Draw Mode:

InflaRx NV Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 111.84M 44.20M 39.81M $ - $ - -1.25 -2.80
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - -

more financials information »

InflaRx NV News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical IFRX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.173.172.262.76305,017-0.64-20.19%
1 Month1.433.181.322.25882,8191.1076.92%
3 Months1.383.180.77621.83631,2551.1583.33%
6 Months3.243.260.77621.90418,670-0.71-21.91%
1 Year2.385.68560.77623.551,039,9070.156.3%
3 Years2.649.700.77624.17721,575-0.11-4.17%
5 Years15.1953.100.77625.51578,998-12.66-83.34%

InflaRx NV Description

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
Your Recent History
NASDAQ
IFRX
InflaRx NV
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220818 17:40:34